Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high189.98 29/03/17
52 week low10.50 08/01/18
52 week change -87.00 (-79.09%)
4 week volume234,379 25/12/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
28/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
15/05/2014

Latest NewsMore

Issue of Equity

RNS Number: 0634C Akers Biosciences, Inc. 16 January 2018 January 16, 2018 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, pursuant to the Public Offering announced on December 19, 2017, the Company has receive...

Update RE Admission of Shares

RNS Number: 8088B Akers Biosciences, Inc. 15 January 2018 January 15, 2018 Akers Biosciences, Inc. Update Re: Admission of Shares Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, provides an update on the admission of shares previously announced in the Issue of Equity...

Akers Biosciences in equity issue

Akers Biosciences has issued 9,366,668 common shares after receiving applications for the conversion of 1,405 shares of serie...

Issue of Equity

RNS Number: 6720B Akers Biosciences, Inc. 12 January 2018 January 12, 2018 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, pursuant to the Public Offering announced on December 19, 2017, the Company has receiv...

Issue of Equity

RNS Number: 1592B Akers Biosciences, Inc. 05 January 2018 January 5, 2018 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, pursuant to the Public Offering announced on December 19, 2017, the Company has receive...

Holdings in Company

RNS Number: 0248B Akers Biosciences, Inc. 04 January 2018 January 4, 2018 Akers Biosciences, Inc. Holdings in Company Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, on January 2, 2018, Bigger Capital Funds, LP disclosed that, as of such date, it owned...

Issue of Equity

RNS Number: 3803A Akers Biosciences, Inc. 27 December 2017 December 27, 2017 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, pursuant to the Public Offering announced on December 19, 2017, the Company has r...

Akers Bio public offering closes

Akers Biosciences has announced the closing of the underwritten public offering, for total gross proceeds of $6,900,000, gro...

Latest discussion posts More

  • BUY BUY BUY

    Could be a good time ahead for Akers . Investors value us way above current MCAP . DO NOT Miss out Best of Luck All Current 25 cents per share
    17-Jan-2018
    Gold or Silver
  • About time

    For a change here . 45 million shares can`t be wrong . Can they ? Best of Luck ALL
    9-Jan-2018
    Gold or Silver
  • Re: Finncap very positive

    "House broker finnCap" - Except that the first two words that were all you needed to read... Disaster!
    19-Dec-2017
    RichardLY

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account